These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
284 related articles for article (PubMed ID: 27230923)
21. Reliability of dopamine transporter PET measurements with [ Kerstens VS; Fazio P; Sundgren M; Matheson GJ; Franzén E; Halldin C; Cervenka S; Svenningsson P; Varrone A EJNMMI Res; 2020 Aug; 10(1):95. PubMed ID: 32797307 [TBL] [Abstract][Full Text] [Related]
22. Kinetic analysis and quantification of the dopamine transporter in the nonhuman primate brain with 11C-PE2I and 18F-FE-PE2I. Varrone A; Tóth M; Steiger C; Takano A; Guilloteau D; Ichise M; Gulyás B; Halldin C J Nucl Med; 2011 Jan; 52(1):132-9. PubMed ID: 21189414 [TBL] [Abstract][Full Text] [Related]
23. Low dopamine transporter binding in the nucleus accumbens in geriatric patients with severe depression. Moriya H; Tiger M; Tateno A; Sakayori T; Masuoka T; Kim W; Arakawa R; Okubo Y Psychiatry Clin Neurosci; 2020 Aug; 74(8):424-430. PubMed ID: 32363761 [TBL] [Abstract][Full Text] [Related]
24. Quantitative analysis of dopamine transporters in human brain using [11C]PE2I and positron emission tomography: evaluation of reference tissue models. Seki C; Ito H; Ichimiya T; Arakawa R; Ikoma Y; Shidahara M; Maeda J; Takano A; Takahashi H; Kimura Y; Suzuki K; Kanno I; Suhara T Ann Nucl Med; 2010 May; 24(4):249-60. PubMed ID: 20364374 [TBL] [Abstract][Full Text] [Related]
25. Li W; Lao-Kaim NP; Roussakis AA; Martín-Bastida A; Valle-Guzman N; Paul G; Loane C; Widner H; Politis M; Foltynie T; Barker RA; Piccini P Mov Disord; 2018 Jan; 33(1):117-127. PubMed ID: 29082547 [TBL] [Abstract][Full Text] [Related]
26. Simplified quantification and whole-body distribution of [18F]FE-PE2I in nonhuman primates: prediction for human studies. Varrone A; Gulyás B; Takano A; Stabin MG; Jonsson C; Halldin C Nucl Med Biol; 2012 Feb; 39(2):295-303. PubMed ID: 22033024 [TBL] [Abstract][Full Text] [Related]
27. Synthesis, radiolabeling and preliminary in vivo evaluation of [18F]FE-PE2I, a new probe for the dopamine transporter. Schou M; Steiger C; Varrone A; Guilloteau D; Halldin C Bioorg Med Chem Lett; 2009 Aug; 19(16):4843-5. PubMed ID: 19577467 [TBL] [Abstract][Full Text] [Related]
29. Principal Component Analysis of Multimodal Neuromelanin MRI and Dopamine Transporter PET Data Provides a Specific Metric for the Nigral Dopaminergic Neuronal Density. Kawaguchi H; Shimada H; Kodaka F; Suzuki M; Shinotoh H; Hirano S; Kershaw J; Inoue Y; Nakamura M; Sasai T; Kobayashi M; Suhara T; Ito H PLoS One; 2016; 11(3):e0151191. PubMed ID: 26954690 [TBL] [Abstract][Full Text] [Related]
30. Quantification of dopamine transporter density with [18F]FECNT PET in healthy humans. Nye JA; Votaw JR; Bremner JD; Davis MR; Voll RJ; Camp VM; Goodman MM Nucl Med Biol; 2014 Mar; 41(3):217-22. PubMed ID: 24533985 [TBL] [Abstract][Full Text] [Related]
31. Measurement of striatal and extrastriatal dopamine transporter binding with high-resolution PET and [11C]PE2I: quantitative modeling and test-retest reproducibility. Hirvonen J; Johansson J; Teräs M; Oikonen V; Lumme V; Virsu P; Roivainen A; Någren K; Halldin C; Farde L; Hietala J J Cereb Blood Flow Metab; 2008 May; 28(5):1059-69. PubMed ID: 18183028 [TBL] [Abstract][Full Text] [Related]
32. Clinical correlates of dopamine transporter availability in cross-sectional and longitudinal studies with [ Honhar P; Ebrahimian Sadabad F; Tinaz S; Gallezot JD; Dias M; Naganawa M; Yang Y; Henry S; Hillmer AT; Gao H; Najafzadeh S; Comley R; Nabulsi N; Huang Y; Finnema SJ; Carson RE; Matuskey D Brain Commun; 2024; 6(5):fcae345. PubMed ID: 39429243 [TBL] [Abstract][Full Text] [Related]
33. Quantitative analyses of regional [11C]PE2I binding to the dopamine transporter in the human brain: a PET study. Jucaite A; Odano I; Olsson H; Pauli S; Halldin C; Farde L Eur J Nucl Med Mol Imaging; 2006 Jun; 33(6):657-68. PubMed ID: 16514530 [TBL] [Abstract][Full Text] [Related]
34. PE2I: a radiopharmaceutical for in vivo exploration of the dopamine transporter. Emond P; Guilloteau D; Chalon S CNS Neurosci Ther; 2008; 14(1):47-64. PubMed ID: 18482099 [TBL] [Abstract][Full Text] [Related]
35. VNTR polymorphism in the SLC6A3 gene does not influence dopamine transporter availability measured by [18F]FE-PE2I PET or [123I]FP-Cit SPECT. Jakobson Mo S; Axelsson J; Stiernman LJ; Larsson A; Af Bjerkén S; Bäckström D; Kellgren TG; Varrone A; Riklund K Nucl Med Commun; 2022 Mar; 43(3):247-255. PubMed ID: 34908018 [TBL] [Abstract][Full Text] [Related]
36. Quantification of 18F-JNJ-42259152, a novel phosphodiesterase 10A PET tracer: kinetic modeling and test-retest study in human brain. Van Laere K; Ahmad RU; Hudyana H; Dubois K; Schmidt ME; Celen S; Bormans G; Koole M J Nucl Med; 2013 Aug; 54(8):1285-93. PubMed ID: 23843566 [TBL] [Abstract][Full Text] [Related]
37. PET imaging of [ Varnäs K; Cselényi Z; Jucaite A; Halldin C; Svenningsson P; Farde L; Varrone A Eur J Nucl Med Mol Imaging; 2019 Feb; 46(2):367-375. PubMed ID: 30270409 [TBL] [Abstract][Full Text] [Related]
38. Whole-body distribution and radiation dosimetry of the dopamine transporter radioligand [(11)C]PE2I in healthy volunteers. Ribeiro MJ; Ricard M; Lièvre MA; Bourgeois S; Emond P; Gervais P; Dollé F; Syrota A Nucl Med Biol; 2007 May; 34(4):465-70. PubMed ID: 17499737 [TBL] [Abstract][Full Text] [Related]
39. [(11)C]PE2I: a highly selective radioligand for PET examination of the dopamine transporter in monkey and human brain. Halldin C; Erixon-Lindroth N; Pauli S; Chou YH; Okubo Y; Karlsson P; Lundkvist C; Olsson H; Guilloteau D; Emond P; Farde L Eur J Nucl Med Mol Imaging; 2003 Sep; 30(9):1220-30. PubMed ID: 12811422 [TBL] [Abstract][Full Text] [Related]